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Abstract
Hepatocyte growth factor (HGF), a stimulator of angiogenesis and cell migration, regu-
lates the growth of a wide variety of cells by binding to its high-affinity receptor met and
is involved in the growth and aggressiveness of several tumors. In this study we investi-
gated the expression of HGF and met in normal endocrine cells and related neoplasms of
the gut and pancreas to verify their possible role in tumor pathogenesis, growth, and
aggressiveness. Normal tissues and 60 different endocrine tumors were immunostained
using specific antibodies directed against HGF, met, and various hormones. HGF immuno-
reactivity (IR) was found in antroduodenal G cells, rectal enterochromaffin (EC) cells, and
pancreatic A and B cells, whereas met IR was detected in antral EC and G cells, and in
pancreatic B cells; 46 of 60 tumors examined were positive for HGF, and they were mainly
represented by ECL-, EC-, and L-cell neoplasms. met IR was identified in 50/60 tumors of
various phenotypes. HGF and met coexpression was found in 42/60 cases, most of which
were represented by EC-cell tumors. HGF/met coexpression was significantly more fre-
quent in ileocolonic EC-cell tumors, which in the majority of cases were malignant, than
in appendiceal EC-cell tumors, which were all benign. Our results demonstrated, for the
first time, that HGF and met are specifically distributed in normal gut and pancreatic
endocrine cells and, in addition, suggest that HGF and met may be implicated as
autocrine/paracrine factors regulating the growth of gastroenteropancreatic endocrine
tumors, mainly of ileocolonic EC-cell carcinoids.
Key Words: Hepatocyte growth factor; met; endocrine tumor; gut; pancreas; immuno-
histochemistry.
Introduction
Growth factors are polypeptides that
stimulate cell proliferation and differentia-
tion, and, furthermore, are able to regu-
late cell motility and cytoskeletal structure
[1]. Their biological activities depend on
binding to specific high-affinity cell mem-
brane receptors. Unlike hormones, growth
factors are often produced by more than
one cell type, show a wide range of over-
lapping biological actions, and generally act
over short distances either in a paracrine
or in an autocrine fashion [2].
Among the large number of growth fac-
tor peptides discovered in the last few years,
hepatocyte growth factor (HGF), also
known as scatter factor, has been recently
reported as an important peptide that
stimulates angiogenesis [3] and regulates the
growth of hepatocytes and cells distributed
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in several tissues, including kidney, pla-
centa, brain, lung, and pancreas [4,5].
HGF, encoded by a gene located on chro-
mosome 7, was originally identified in rat
serum after partial hepatectomy [6]. It is a
heterodimer glycoprotein consisting of a
heavy α-chain and a light β-chain, held
together by disulfide bonds [7]. It is secreted
as an inactive single-chain precursor that
needs proteolytic cleavage to become a
mature biologically active heterodimer
[8,9]. HGF, first recognized as a growth
factor implicated in liver regeneration,
exerts a wide spectrum of biological actions
on many cell types, especially of epithelial
and endothelial origin [3,4]. These actions
comprise mitogenic activity for hepatocytes
and various other epithelial cells, a power-
ful motogenic (scattering) effect on several
epithelial cell lines in vitro [10] a morpho-
genic effect (tubule formation) on kidney
tubular cells [11] and breast carcinoma cells
[12], and an angiogenic effect, which is due
to mitogenic and motogenic stimulation
of vascular endothelial cells [13].
HGF exerts its biological activities
through the binding to a high-specific-
transmembrane type II tyrosine kinase
receptor (met), encoded by the proto-
oncogene c-met, located on chromosome
7 [14–17]. Met is highly expressed in sev-
eral normal epithelial adult tissues, includ-
ing pancreas, stomach, intestine, skin,
uterus, lung, and kidney [15,18], although
it does not seem to be expressed in mesen-
chymal cells [17]. In addition, met has been
detected in fetal epithelial cells of stomach
and pancreas and fetal endocrine cells of
the gut [19]. This widespread distribution
of HGF and met in several adult and fetal
normal tissues suggests their importance
in regulation of growth, morphogenesis,
and cell functions of several tissues.
The presence of HGF and met, some-
times simultaneously, in different types of
human neoplasms, including those of the
breast [20], melanocytes [21], pancreas
[22,23], prostate [24], stomach [25],
peripheral nerve sheath [26], and thyroid
[27] suggests that HGF and its receptor
may be involved in tumor pathogenesis,
and growth and development of distant
metastases.
Endocrine tumors of the gut and pan-
creas represent a heterogeneous group of
neoplasms, whose pathogenesis and
mechanisms of tumor progression are
unknown. They have been recently found
to express several growth factors and
growth factor receptors, including TGFα,
EGFR, TGFβ, PDGF, insulin-like growth
factor-I, VEGF, activin A, aFGF, bFGF,
and FGFR4 [28–40]. The precise role of
these peptides remains unclear, although
they seem to be implicated, at least as
regards ECL-cell and EC-cell carcinoids,
in the pathogenesis of stromal lesions and
of smooth muscle layer hyperplasia associ-
ated with these tumors [30,37,39].
To verify whether HGF and met are
involved in the pathogenesis, growth, and
metastatic dissemination of gut and pan-
creatic endocrine tumors, we investigated
their expression in a series of 60 endocrine
tumors, and, in comparison, in normal
endocrine cells of the gut mucosa and pan-
creatic islets.
Materials and Methods
Sixty endocrine tumors of the gut and
pancreas and samples of normal adult pan-
creatic, gastric, and intestinal tissues were
collected at surgery, fixed in buffered for-
malin (formaldehyde 4% w/v and acetate
buffer 0.05 M, pH 7.4) for 24 h and
embedded in paraffin. Sections were
stained with hematoxylin–eosin (H&E)
and Grimelius’ silver impregnation for the
routinely histopathologic evaluation. For
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Table 1. Antisera and Antibodies Employed
Antibodies/antisera P/M (clone)a Dilution Source
Insulin (Ins) M (AE9D6) 1:200 BioGenex Laboratories, San Ramon, CA
Glucagon (Gluc) P 1:1250 Milab, Malmo, Sweden
Glucagon/glicentin (Glic) P 1:2500 Milab
Pancreatic polypeptide (PP) P 1:4000 Cambridge Research Biochemicals,
Cambridge, UK
Somatostatin (Som) P 1:500 Dako, Copenhagen, Denmark
Serotonin (5HT) M (YC5) 1:50 Biogenesis, Bournemouth, UK
C-terminus gastrin-CCK-cerulein (Gastr) M (B4) 1:10000 Farmitalia, Milan, Italy
Gastrin 34 (G34) P 1:500 Cambridge Research Biochemicals
Secretin (Secr) P 1:500 Milab
Peptide YY (PYY) P 1:1000 Biogenesis
Hepatocyte growth factor (HGF) P 1:1000 Serotec, Oxford, UK
Hepatocyte growth factor (HGF) P 1:100 Sigma, St. Louis, MO
Hepatocyte growth factor (HGF) M (DV-14) 1:50 Dr. M. Prat, Novara, Italy
Met receptor (met) P 1:200 Santa Cruz Biotechnology, Inc,
Santa Cruz, CA
Met receptor (met) M (8F11) 1:100 Novocastra, Newcastle, UK
aP = polyclonal; M = monoclonal.
immunohistochemical stains, 3-µm-thick
sections were mounted on poly-L-lysine–
coated slides and then deparaffinized and
hydrated through graded alcohols to
water. Endogenous peroxidase activity was
removed by dipping sections into 3% hydro-
gen peroxide for 10 min at room tempera-
ture. Thereafter, sections were incubated
with the antibodies listed in Table 1 for
20 h at 4°C and then the avidin–biotin–
peroxidase complex (ABC) procedure was
performed. The peroxidase activity was
finally revealed by 0.03% 3,3'-diamino-
benzidine, and the nuclei were counterstained
with Harris’ hematoxylin. Colocalization
studies were performed on serial paraffin
sections, semithin-plastic sections, and
using double label immunostains as previ-
ously described [30].
The localization of HGF was obtained
using three different specific antibodies, as
reported in Table 1. In detail, the anti-HGF
antibody purchased from Sigma (St. Louis,
MO) was a goat polyclonal antibody
directed against recombinant human HGF.
The anti-HGF antibody, provided by
Serotec (Oxford, UK), was a sheep
polyclonal antibody whose immunogen
was a highly purified human HGF. The
monoclonal anti-HGF antibody (clone
DV-14) was raised using recombinant
HGF secreted by the Spodoptera frugiperda
insect cells (Sf9), which were infected with
the baculovirus vector containing the full
size human HGF cDNA, as immunogen
[41]. For met protein detection, we
employed a mouse monoclonal antibody
recognizing the external domain of the beta
chain of the c-met molecule, purchased
from Novocastra (Newcastle, UK), and a
rabbit polyclonal antibody raised against a
2.5 kDa peptide mapping at the carboxy
terminus of human met, made by Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA).
Sections incubated with the antibodies
directed against N-terminal glucagon-
glicentin and somatostatin were pretreated
with 0.003% subtilisin (Sigma, P4789;
protease type XXVII or Nagarse protease)
in 0.05 M Tris-buffered saline pH 7.4. Sec-
tions immunostained using both anti-met
antisera and the anti-HGF goat antibody,
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Table 2. Immunohistochemical Localization of HGF and met in Normal Endocrine
Cells of the Gut and Pancreas Using Different Antibodiesa
HGF met
Serotec Sigma Novocastra Santa Cruz
Fundus – – – –
Antrum – G G, EC G, EC
Duodenum – G Rare Rare
Jejunum – – – –
Ileum – – – –
Appendix – – – –
Right colon – – – –
Rectum EC EC – –
Pancreas – A, B B B
aG = gastrin-producing G-cells; EC = serotonin-producing enterochromaffin cells; A = glu-
cagon-producing A cells; B = insulin-producing B cells.
were pretreated with 0.01 M citrate buffer
pH 6 for 10 min in a microwave oven at
650 W.
Specificity controls consisted of absorp-
tion of the antibody with 10–20 nmol of
the related antigen, substitution of the pri-
mary antibody with nonimmune serum of
the same species at the same dilution, and
use of control tissues with or without the
pertinent antigen. In addition, the speci-
ficity of the Sigma anti-HGF antibody and
of the Santa Cruz anti-met antibody has
been tested according to the criteria previ-
ously reported by Kermorgant et al. [19].
The specificity of the monoclonal anti-
HGF (clone DV-14) antibody has been
previously confirmed by molecular biology
techniques [41].
The evaluation of HGF and met
immunoreactivities in normal endocrine
cells was performed either on tissues
from patients without endocrine tumors
or on tissues obtained from peritumoral
regions of the 60 endocrine tumors
investigated.
Statistical evaluation of results was per-
formed using the Fisher exact test. Two
values were considered statistically differ-
ent when p < 0.05.
Results
Normal Tissues
In normal tissues we have found some
differences regarding HGF expression in
relation to the different antibodies employed
(Table 2). Using the sheep polyclonal
antibody directed against purified human
HGF, HGF-positive cells were not identi-
fied in pancreatic islets or in gastric, duode-
nal, ileal, appendiceal, and right colon
mucosae. On the contrary, HGF-immuno-
reactive (IR) cells were found in the rectal
mucosa (Fig. 1), where they were mostly
located in the lower part of crypts.
Immunopositivity was cytoplasmic, dark
brown, and granular. Double immuno-
stains demonstrated that the rectal HGF-
IR endocrine cells represented a subgroup
(about 90%) of enterochromaffin (EC)
cells, coexpressing serotonin, whereas HGF
was not expressed in rectal endocrine cells
containing other hormones such as
glicentin, PYY, and somatostatin. With the
goat polyclonal antibody directed against
recombinant human HGF, in addition to
rectal EC cells, some gastric and duodenal
G cells resulted in HGF-IR (Fig. 2A).
Moreover, several islet cells resulted that
were more or less intensely stained by
this antibody (Fig. 2B). The immuno-
reactivity was intense in a subgroup of glu-
cagon-producing A cells and weak in
insulin-producing B cells. The pattern of
immunoreactivity was similar to that
observed using the antibody directed
against purified human HGF, showing a
dark brown and granular staining in the
cytoplasm of cells. In addition to endo-
crine cells, other types of epithelial cells of
the gut and pancreas, including foveolar
and chief cells of gastric mucosa, colum-
nar cells of small intestinal villi, epithelial
cells of the colonic mucosa and duct, and
acinar cells of the pancreas, were HGF-IR
with both anti-HGF antibodies employed.
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Fig. 1. Immunolocalization of HGF in scattered
endocrine cells of the rectal mucosa. Original mag-
nification ×400.
Fig. 2. HGF immunoreactivity in endocrine cells of the duodenal mucosa (A) and of a pancreatic islet (B).
Original magnification ×400.
The two anti-met antibodies gave simi-
lar patterns of immunoreactivity, although
the monoclonal antibody generally showed
a more intense positivity in epithelial cells
than the polyclonal one. On the contrary,
stromal and endothelial cells were more
intensely stained by the polyclonal than
the monoclonal anti-met antibody. A dis-
crete number of met-IR endocrine cells was
found in antral mucosa, and colocalization
studies demonstrated that they corre-
sponded to a subpopulation of gastrin-pro-
ducing (G) and serotonin-producing (EC)
cells (Figs. 3 and 4). The immunoreactiv-
ity was cytoplasmic, although, in some
cells, a membrane enhancement was evi-
dent. In addition to the gastric antrum,
very few met-IR endocrine cells were
present in the duodenal mucosa, although
they were lacking in all the remaining tracts
of the gut investigated. In the pancreas, an
intense immunostaining for met was found
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Fig. 3. Semithin serial sections of antral mucosa showing met immunoreactivity (A) in a subgroup of gas-
trin-positive cells (B). Original magnification ×630.
Fig. 4. Semithin serial sections of antral mucosa showing met IR (A) in some serotonin-positive cells (B) (arrows).
Original magnification ×630.
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in islet cells (Fig. 5), which, by the colocali-
zation studies, appeared to be insulin pro-
ducing B cells. Met immunoreactivity was
also detected in epithelial nonendocrine
cells of the gut and pancreas, including
gastric foveolar and chief cells, columnar
cells of the intestine, Brunner glands,
colonic crypt cells, and duct and acinar cells
of the pancreas. In addition to epithelial
cells, endothelial and smooth muscle cells
of the gut and pancreas were also met-IR.
Endocrine Tumors
The 60 endocrine tumors studied
included 14 pancreatic and 46 gut (8 gas-
tric, 6 duodenal, 1 jejunal, 10 ileal, 12 appen-
diceal, 3 right colon, 6 rectal) neoplasms.
The clinico-pathologic features of these
tumors are summarized in Table 3. Lymph
node and distant metastases and local
invasion were found in 29 cases (23 gut
and 6 pancreatic tumors).
HGF-immunoreactive cells were iden-
tified in gastroenteropancreatic (GEP)
endocrine tumors using the three differ-
ent anti-HGF antibodies (Table 1). The
results regarding the HGF expression,
obtained using the two polyclonal anti-
HGF antibodies, were concordant in
34/49 tumors tested; in cases positive for
both antibodies, the number of positive
cells was sometimes different in relation to
the antibody employed. With the antise-
rum directed against purified human HGF,
immunoreactive cells were found in 32/60
Fig. 5. Serial section showing that the majority of insulin-immunoreactive B cells (A) are also positive for met (B) (×200). The insets show a
detail demonstrating the colocalization.
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(53%) tumors, whereas with the antibody
directed against recombinant human HGF,
they were detected in 38/49 (77%) tumors.
In general, the second of the two antibod-
ies mentioned above appeared to be more
sensitive than the first one in detecting
HGF-IR cells. Owing to the small amount
of the antibody available, eight selected
tumors (cases 8, 11, 14, 18, 28, 40, 45,
58) were tested with the monoclonal (clone
DV-14) anti-HGF antibody. The results
confirmed well those obtained with the
polyclonal antibody directed against the
recombinant HGF. Although HGF-IR
tumors were located in all sites of the GEP
system, the majority of them were in
the stomach, ileum, and rectum, and cor-
responded to gastric ECL-cell, ileocolonic
EC-cell, and rectal and appendiceal L-cell
tumors. Immunoreactivity was generally
diffuse and intense in the cytoplasm,
although, with the polyclonal antibody
directed against human purified HGF and
with the monoclonal anti-HGF antibody,
some cells showed paranuclear dot-like
positivity. Among EC-cell tumors, a HGF-
IR was found in 7/11 (63%) appendiceal
cases and in 13/15 (86.6%) ileocolonic
neoplasms. Ten of 14 (71%) pancreatic
neoplasms were HGF-IR for at least one
of the two antibodies and the immuno-
reactivity did not appear to be restricted
to a unique tumor type, being found in
one insulinoma, one gastrinoma, two
VIPomas, and four nonfunctioning tumors
(three well and one poorly differentiated).
Met immunoreactivity for at least one
of the two anti-met antibodies employed
was found in 50/60 (83.3%) tumors. In only
seven cases a met-IR was obtained with only
one of the two antibodies employed, while
in the remaining neoplasms tested with
both antibodies, results were similar in
terms of positive or negative staining. How-
ever, in some cases we observed a different
percentage of met-IR cells depending on
the antibody employed. Met-IR was
intense and cytoplasmic, with a membrane
enhancement in some cells (Fig. 6), espe-
cially with the polyclonal antibody. Met-
positive endocrine tumors for at least
one of the two antibodies were located in
all sites of the GEP system and included
6/6 ECL-cell and 2/2 PDEC of the stom-
ach, 15/15 ileocolonic EC-cell carcinoids,
3/4 D-cell and 2/2 G-cell tumors of the
duodenum, and 5/5 rectal and appendiceal
L-cell carcinoids. However, in the appen-
dix and pancreas met-IR tumors were less
numerous. In particular, in the appendix
they were 7/10 (70%) EC-cell carcinoids
and in the pancreas 9/14 (64%) endocrine
tumors including three insulinomas, one
VIPoma, one gastrinoma, and four non-
functioning neoplasms. Metastases and/or
local invasion were present in 22/48 (46%)
met-IR and 5/9 (55%) met-negative tumors,
without any significant difference in rela-
Fig. 6. Met-IR in a pancreatic insulinoma localized
at membrane level in some cells.
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Metastases *Ab anti-HGF Ab anti-HGF
N Sex Age Site Type Size (cm) or invasion purified recombinant Met MAb Met PAb
  1 F 65 Stomach Type 1^ NE No 0 100 90 90
  2 F 90 Stomach Type 1 NE No 0 NE 90 NE
  3 M 76 Stomach Type 1   2 No 5 5 40 20
  4 M 43 Stomach Type 3^   2 Node 10 3 100 0
  5 M 26 Stomach Type 3   2 Node/liver 10 NE 90 NE
  6 F 56 Stomach Type 3   8.3 Node 0 90 100 70
  7 M 68 Stomach PDEC   3 Node/liver 5 0 60 30
  8 M 52 Stomach PDEC   5 Node 60 100 60 30
  9 F 52 Duodenum D cell   1.5 Node 0 0 0 0
10 F 38 Duodenum D cell   1 Node 10 10 100 60
11 F 46 Duodenum D cell   2.5 Node/liver 0 90 60 70
12 M 52 Duodenum D cell   4 Node 0 0 40 40
13 F 42 Duodenum G cell   1 No 0 3 90 90
14 F 55 Duodenum G cell   0.5 No 3 100 80 80
15 F 38 Jejunum Undefined cell   1.2 Node/liver 3 5 100 60
16 F 67 Ileum EC cell   2 Node/liver 0 0 100 5
17 M 52 Ileum EC cell   2 Node/liver 20 20 100 90
18 M NE Ileum EC cell   2.5 No 30 80 100 50
19 F 46 Ileum EC cell   1.5 Node 60 20 80 80
20 M 59 Ileum EC cell   2.5 Liver 20 20 100 100
21 M 58 Ileum EC cell   2.5 Node/liver 50 NE 70 NE
22 M 39 Ileum EC cell   3 Node 70 90 80 50
23 F 75 Ileum EC cell   1.5 Liver 0 0 80 80
24 F 69 Ileum EC cell   2 Node 20 20 70 50
25 M 72 Ileum EC cell   1 Omentum 20 2 20 80
26 M 53 Appendix EC cell   2.5 No 0 50 0 90
27 M 25 Appendix EC cell   0.5 No 0 NE 0 0
28 F 95 Appendix EC cell   2 No 0 60 30 60
29 F 14 Appendix EC cell   0.6 No 0 0 0 0
30 F 17 Appendix EC cell   0.5 No 0 30 0 30
31 F 24 Appendix EC cell   0.2 No 0 40 0 80
32 M 27 Appendix EC cell   0.5 No 0 NE 60 NE
33 F 21 Appendix EC cell   0.3 No 40 NE 100 NE
34 M 27 Appendix EC cell   1 No 0 20 0 0
35 F 15 Appendix EC cell   0.2 No 0 NE 0 0
36 F 42 Appendix EC cell   0.9 No 0 0 80 80
37 F 24 Appendix L cell   1.5 No 60 60 100 100
38 NE NE Right colon EC cell NE Liver 20 NE 90 50
39 F 50 Right colon EC cell NE Omentum 0 90 100 80
40 M 46 Right colon EC cell   8 Liver 40 90 100 80
41 F 51 Rectum L cell   0.7 No 60 NE 100 NE
42 F 66 Rectum L cell NE No 70 NE 40 NE
43 M 39 Rectum L cell   0.3 No 40 80 80 30
44 M 54 Rectum EC cell   2 No 10 10 100 100
45 M 66 Rectum L cell   1 No 70 60 100 90
46 M 70 Rectum EC/L cell   2 Liver 90 90 90 30
47 F 52 Pancreas Somatostatinoma   5 Duodenum 0 0 0 0
48 F 53 Pancreas Insulinoma   2.5 No 0 0 10 100
49 F 54 Pancreas Insulinoma   1 No 10 0 80 100
50 M 85 Pancreas Insulinoma NE No 0 0 80 10
51 F 40 Pancreas Gastrinoma   2 Liver/node 40 100 0 50
52 M 72 Pancreas VIPoma 10 No 5 100 70 80
53 F 57 Pancreas VIPoma   5 Liv/node/brain 0 70 0 0
54 M 62 Pancreas NF   3 Duodenum 5 60 0 0
55 F 66 Pancreas NF (gluc)   1.2 No 0 100 40 0
56 F 62 Pancreas NF (gluc)   1.7 No 0 NE 30 NE
57 F 50 Pancreas NF (5HT)   2 No 0 60 70 5
58 F 75 Pancreas NF (5HT)   3 No 0 100 0 0
59 F 59 Pancreas NF (PP)   8 Liver/node 60 60 0 10
60 M 58 Pancreas PDEC   3.5 Liver/node 5 1 0 0
aAb = antibody; MAb = monoclonal antibody; PAb = polyclonal antibody; * = percentage of positive cells; ^ = classified according to Rindi et al. [52];
NE = not evaluated; PDEC = poorly differentiated endocrine carcinoma; NF = nonfunctioning.
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tion to tumor type. Among gut EC-cell
carcinoids, 13/22 (59%) met-IR tumors
were metastatic and/or invasive, while none
of the four met-negative EC-cell tumors
(all localized in the appendix) was associ-
ated with metastases (p = 0.04).
Coexpression of HGF and met in the
same tumor was found in 42/60 (70%)
cases, 21 of which (50%) were metastatic
or locally invasive (Table 3). The majority
of cases showing HGF and met coexpres-
sion were gastric ECL-cell (6/6 cases), ileo-
colonic EC-cell (13/15 cases) (Fig. 7), and
rectal L-cell tumors (4/4 cases). Among
them, metastases or gross invasion of adja-
cent organs or vessels were observed in type
III gastric ECL-cell, and in EC-cell tumors.
Among 18 tumors not expressing HGF
and met or expressing only one of them,
8 showed metastases or local invasion
(Table 3). Considering neoplasms, with-
out differentiating them in relation to cell
type and site, the biological aggressiveness
of HGF/met-positive tumors was not sta-
Fig. 7. Serial sections of an ileal EC-cell tumor indicating that neoplastic cells express HGF (A) and met (B)
(×1000).
tistically different from that of tumors
expressing only one or none of these pro-
teins. In the group of gut EC-cell neoplasms,
coexpression of HGF/met statistically (p =
0.03) correlates with tumor site, in fact it
was found in 13/15 (86.6%) ileocolonic
EC-cell tumors, 11 of which (85%) were
malignant, and in 5/11 (45%) appendiceal
EC-cell neoplasms, which were all benign.
Peritumoral tissues were evaluated in
43 cases. They were histologically normal,
with the exception of mucosae neighbor-
ing the three type 1 gastric ECL-cell
carcinoids, which showed histological fea-
tures of chronic autoimmune atrophic
gastritis with intestinal and pseudopyloric
metaplasia. The pattern and distribution
of immunoreactivity for HGF and met in
peritumoral examined reflected those
observed in normal tissues not associated
with endocrine tumors. In particular, the
majority of foveolar and chief gastric cells,
columnar cells of small intestinal villi,
colonic crypt cells, some duct and acinar
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pancreatic cells were HGF and met-IR,
the latter being also expressed in Brunner
gland cells.
Discussion
Growth factors are polypeptides that
interact with specific receptors to modu-
late several cell functions, such as prolif-
eration, differentiation, and motility [1].
In addition, growth factors are also involved
in mechanisms regulating tumorigenesis,
during which cells lose their normal physi-
ologic functions and acquire an aggressive
phenotype. HGF and its receptor met have
been found to play physiologic roles in
gastric ulcer healing [42,43] and human
organogenesis [44], but they also seem to
be involved in tumorigenesis and progres-
sion of several malignancies [18,20–25].
In this study, we have investigated the
immunohistochemical expression of HGF
and met in endocrine cells of the digestive
system and in a series of GEP endocrine
tumors. Immunohistochemistry, and par-
ticularly double label techniques, is useful
in demonstrating the presence of two or
more antigens within the same cell. The
introduction of microwave-oven heating in
the double-immunostaining technique has
eliminated major drawbacks related to
antibodies crossreactivity and has provided
several advantages over traditional meth-
ods [45]. In this study we simultaneously
used double label immunostainings and the
ABC-immunohistochemical technique on
serial paraffin and semithin-plastic sections
to eliminate possible doubts of interpreta-
tion in the localization of HGF and met
in specific cell types.
HGF and met appeared to be localized
in specific endocrine cell types of the gut
and pancreas. Although the two anti-HGF
antibodies employed were specific, there
were differences between them in terms of
sensitivity. The antibody directed against
human recombinant HGF seemed to be
more sensitive than that directed against
purified human HGF, in fact the former
antibodies detected a greater number of
HGF-positive cells in the various tumors
investigated. In addition, in normal tissues
the antibody directed against the recom-
binant peptide recognized HGF in G cells
of the duodenal mucosa, and in A and B
cells of pancreatic islets, which resulted
negative when investigated with the anti-
body directed against the purified peptide.
Regarding the two anti-met antibodies
(monoclonal and polyclonal), we did not
find significant differences in the distribu-
tion of positive cells, although the mono-
clonal antibody gave a more intense
staining of epithelial cells, whereas the
polyclonal antibody presented a stronger
immunoreactivity of endothelial and stro-
mal cells in comparison to epithelial cells.
The localization of HGF and met in
normal endocrine cells of the human adult
gut was restricted to G cells of the antral
and duodenal mucosa, which expressed
both these proteins. In addition, in the
gastric antrum met-IR was also localized
in EC cells. In the rectum, EC cells
expressed HGF but not met. This specific
distribution suggests that in human adult
gut mucosa HGF/met interaction may
have a regulatory function in the biology
of at least gastrin-producing G-cells and
serotonin-producing EC cells. However,
further studies are needed to better clarify
this point.
The wide expression of both HGF and
met in nonendocrine epithelial cells of
mucosal surface and glands suggests that a
paracrine mechanism of regulation may be
operative in local interactions between
endocrine and exocrine cells of the normal
mucosa and among the different types of
exocrine cells. On the basis of our results
it may be hypothesized that there may exist,
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in pyloric mucosa, a paracrine interaction
between exocrine epithelia and G and EC
cells through a HGF/met binding system.
A similar paracrine interaction may be
possible between EC cells of the rectal
mucosa producing HGF and the met-IR
crypt cells. In the pancreas a HGF-IR was
found in A and B cells, whereas a met-IR
was observed only in B cells. Our results
concerning the met expression in islets of
normal human adult pancreas confirms
previous results of Ebert et al. [23] prov-
ing that met is localized in islet cells, aci-
nar cells, and ductal cells. Moreover, we
have demonstrated, for the first time, that
met expression is restricted to B cells. How-
ever, the expression of HGF in the same B
cells and in part of A cells suggests that
there may exist within pancreatic islets an
autocrine/paracrine interaction among A
and B cells through a HGF/met binding.
In addition, an interaction between the
exocrine and endocrine pancreas may be
suggested because the exocrine component
of the gland displayed an immunoreactiv-
ity for both HGF and met. However, the
real functional meaning of the HGF and
met expression in either exocrine or endo-
crine pancreas remains to be clarified, and
needs to be further investigated. As regards
the possible interactions between HGF and
met in islet cells, it is of interest to recall
that HGF has recently been demonstrated
to be capable of enhancing the growth of
human B cells in culture [46]. On the basis
of this report and of our findings, it may
be suggested that HGF produced by
exocrine cells and A and B cells of the pan-
creas may exert a trophic action in an auto-
crine/paracrine fashion on met-expressing
B cells.
In the normal adult tissues investigated,
a HGF/met colocalization was found only
in G cells of the antral mucosa. On the
other hand, their coexpression was detected
in 42/60 (70%) endocrine tumors. Particu-
larly, coexpression was more frequently
found in gastric ECL-cell, ileocolonic
EC-cell, colorectal L-cell neoplasms,
whereas in pancreatic tumors HGF and
met were less frequently coexpressed. These
results suggest the hypothesis that HGF
and met may be implicated as autocrine/
paracrine factors regulating gut endocrine
tumor growth and perhaps development.
In the literature, there is evidence indicat-
ing involvement of HGF and met in the
development and progression of solid
tumors such as sarcomas [26,47,48] and
epithelial malignancies [20,22–25,49],
and, in addition, the tumorigenicity of
HGF and met has recently been demon-
strated in some experimental studies.
Cotransfection of NIH 3T3 cells with met
and HGF resulted in tumorigenesis
[50,51]. Our results also suggest a relation-
ship between HGF/met expression and
tumor aggressiveness in gut EC-cell neo-
plasms. In fact, HGF/met coexpression was
different between ileocolonic EC-cell
carcinoids, which are mostly malignant,
and appendiceal EC-cell tumors, which are
generally benign. The lower expression of
HGF and met in appendiceal EC-cell
tumors may be interpreted as a biological
factor explaining the more favorable behav-
ior of these neoplasms. In this context, it
is interesting to note that a recent report
has shown that appendiceal EC-cell neo-
plasms show an expression of fibroblast
growth factor receptor 4 (FGFR4) lower
than that of ileocolonic EC-cell tumors
[30]. However, although the HGF and met
involvement in gut endocrine tumor
development, growth, and aggressiveness
is an interesting and intriguing hypothesis,
their role in endocrine tumor biology
remains to be clarified, because it is
unknown for certain whether HGF and
met expression is a primary early event in
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tumor development or a secondary event
implicated in tumor progression. Further
studies are needed to better clarify this point.
In conclusion, the results of the present
study demonstrate, for the first time, that
HGF and met are specifically expressed by
different types of normal GEP endocrine
cells and also by various GEP endocrine
tumors, in which they may be implicated
as autocrine/paracrine factors regulating
their growth. The results presented in this
paper can represent the beginning point
for future investigations that will be able
to better clarify the biological and patho-
biological role of HGF and met in the physi-
ology of normal GEP endocrine cells and
in the biology of GEP endocrine tumors.
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